Autologous Total Tumor Mrna Loaded Dotap Liposome Vaccine
Soft Tissue Sarcoma
University of FloridavaccinePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
103 Active assets in the Soft Tissue Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Palbociclib Brown University | Phase 2 | BB |
FILGRASTIM University of California, Irvine | Phase 3 | BB |
Eloxatin OHSU Knight Cancer Institute | Phase 2 | BB |
Inno-206 GI Innovation, Inc. | Phase 3 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Autologous Total Tumor Mrna Loaded Dotap Liposome Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →